Pacific Biosciences Of California (PACB) Common Equity (2010 - 2026)

Pacific Biosciences Of California's Common Equity history runs 17 years deep, the most recent figure standing at $2.4 million for Q1 2026.

• In Q1 2026, Common Equity fell 97.42% year-over-year to $2.4 million; the TTM figure through Mar 2026 stood at $2.4 million (down 97.42% YoY), while the FY2025 annual figure was $5.3 million, down 98.94% from the prior year.
• Common Equity was $2.4 million for Q1 2026 at Pacific Biosciences Of California, down from $5.3 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $763.7 million in Q3 2023 to a low of $2.4 million in Q1 2026.
• Historically, Common Equity has averaged $453.1 million across 5 years, with a median of $562.9 million in 2022.
• The sharpest annual moves came in 2022 and 2025: Common Equity jumped 164.05% in 2022, then slumped 98.94% in 2025.
• A 5-year view of Common Equity shows it stood at $562.9 million in 2022, then grew by 24.59% to $701.3 million in 2023, then slipped by 27.76% to $506.6 million in 2024, then plunged by 98.94% to $5.3 million in 2025, then slumped by 55.77% to $2.4 million in 2026.
• The last three Common Equity figures came in at $2.4 million (Q1 2026), $5.3 million (Q4 2025), and $36.1 million (Q3 2025), per Business Quant data.